Natixis Advisors LLC Boosts Holdings in Sanofi (NASDAQ:SNY)

Key Points

• Natixis Advisors LLC increased its holdings in Sanofi by 1.2%, acquiring an additional 34,964 shares to reach a total of approximately $163.3 million in value.
• Other hedge funds also boosted their stakes in Sanofi, with Eastern Bank increasing its holdings by 121%, highlighting strong institutional interest.
• Analysts regard Sanofi positively, with several upgrades and a consensus price target of $62.00, reflecting optimism about the company's growth potential.

Natixis Advisors LLC grew its stake in Sanofi (NASDAQ:SNY - Free Report) by 1.2% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,944,985 shares of the company's stock after purchasing an additional 34,964 shares during the quarter. Natixis Advisors LLC owned about 0.12% of Sanofi worth $163,329,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in SNY. Eastern Bank increased its stake in Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company's stock valued at $30,000 after purchasing an additional 300 shares in the last quarter. Bessemer Group Inc. increased its stake in Sanofi by 59.8% during the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after purchasing an additional 242 shares in the last quarter. Golden State Wealth Management LLC increased its stake in Sanofi by 619.3% during the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock valued at $35,000 after purchasing an additional 545 shares in the last quarter. UMB Bank n.a. increased its stake in Sanofi by 30.7% during the 1st quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock valued at $62,000 after purchasing an additional 264 shares in the last quarter. Finally, Wayfinding Financial LLC bought a new stake in Sanofi during the 1st quarter valued at about $63,000. 14.04% of the stock is currently owned by institutional investors.

Sanofi Stock Performance

Shares of SNY stock traded up $1.11 during trading hours on Friday, reaching $46.75. The company had a trading volume of 2,518,877 shares, compared to its average volume of 2,122,035. The business has a fifty day moving average price of $49.21 and a 200-day moving average price of $52.09. Sanofi has a one year low of $44.73 and a one year high of $60.12. The firm has a market cap of $114.65 billion, a PE ratio of 11.24, a price-to-earnings-growth ratio of 1.05 and a beta of 0.48. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.69 and a current ratio of 1.37.

Analyst Ratings Changes

SNY has been the subject of a number of analyst reports. Morgan Stanley set a $56.00 price objective on shares of Sanofi in a research note on Monday, June 2nd. Guggenheim restated a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Barclays reaffirmed an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Finally, BNP Paribas began coverage on shares of Sanofi in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price target for the company. Three research analysts have rated the stock with a hold rating, three have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $62.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.